Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis

Vaccine

Volumn 30, Issue 26, 2012, Pages 3957-3964

  Shargh, Vahid Heravi ^a   Jaafari, Mahmoud Reza ^a,b   Khamesipour, Ali ^c   Jaafari, Iman ^a   Jalali, Seyed Amir ^a   Abbasi, Azam ^a   Badiee, Ali ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CpG ODNs; Leishmaniasis; Liposome; SLA; Vaccine

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; LEISHMANIA VACCINE; NUCLEASE; PARASITE ANTIGEN; PHOSPHODIESTER CPG OLIGODEOXYNUCLEOTIDE; PHOSPHOROTHIOATE CPG OLIGODEOXYNUCLEOTIDE; SOLUBLE LEISHMANIA ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME DEGRADATION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE LOAD; PAW EDEMA; PRIORITY JOURNAL; STATIC ELECTRICITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; FEMALE; FOOT; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LEISHMANIASIS; LEISHMANIASIS VACCINES; LIPOSOMES; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PARASITE LOAD;

EID: 84861184574     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.040     Document Type: Article

References (74)

1. Alexander J., Satoskar A.R., Russell D.G. Leishmania species: models of intracellular parasitism. J Cell Sci 1999, 112(18):2993-3002.
2. Modabber F. Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents 2010, 36(Suppl. 1):S58-S61.
3. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006, 19(1):111-126.
4. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol 1995, 89(Suppl. 1):83-88.
5. Khamesipour A., Rafati S., Davoudi N., Maboudi F., Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 2006, 123(3):423-438.
6. Melby P.C. Vaccination against cutaneous leishmaniasis: current status. Am J Clin Dermatol 2002, 3(8):557-570.
7. Noazin S., Khamesipour A., Moulton L.H., Tanner M., Nasseri K., Modabber F., et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis-a meta-analysis. Vaccine 2009, 27(35):4747-4753.
8. Noazin S., Modabber F., Khamesipour A., Smith P.G., Moulton L.H., Nasseri K., et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 2008, 26(52):6759-6767.
9. Wilson K.D., de Jong S.D., Tam Y.K. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Deliv Rev 2009, 61(3):233-242.
10. Krieg A.M., Efler S.M., Wittpoth M., Al Adhami M.J., Davis H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004, 27(6):460-471.
11. Cooper C.L., Davis H.L., Angel J.B., Morris M.L., Elfer S.M., Seguin I., et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19(14):1473-1479.
12. Friedberg J.W., Kim H., McCauley M., Hessel E.M., Sims P., Fisher D.C., et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005, 105(2):489-495.
13. Brown D.A., Kang S.H., Gryaznov S.M., DeDionisio L., Heidenreich O., Sullivan S., et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994, 269(43):26801-26805.
14. Levin A.A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999, 1489(1):69-84.
15. Agrawal S., Temsamani J., Galbraith W., Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995, 28(1):7-16.
16. Sands H., Gorey-Feret L.J., Cocuzza A.J., Hobbs F.W., Chidester D., Trainor G.L. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 1994, 45(5):932-943.
17. Zhao Q., Matson S., Herrera C.J., Fisher E., Yu H., Krieg A.M. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 1993, 3(1):53-66.
18. Krieg A.M., Stein C.A. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?. Antisense Res Dev 1995, 5(4):241.
19. Deng G.M., Nilsson I.M., Verdrengh M., Collins L.V., Tarkowski A. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med 1999, 5(6):702-705.
20. Sparwasser T., Hultner L., Koch E.S., Luz A., Lipford G.B., Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol 1999, 162(4):2368-2374.
21. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10(2):187-192.
22. Kim D., Rhee J.W., Kwon S., Sohn W.J., Lee Y., Kim D.W., et al. Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA. Biochem Biophys Res Commun 2009, 379(2):362-367.
23. Kindrachuk J., Potter J.E., Brownlie R., Ficzycz A.D., Griebel P.J., Mookherjee N., et al. Nucleic acids exert a sequence-independent cooperative effect on sequence-dependent activation of Toll-like receptor 9. J Biol Chem 2007, 282(19):13944-13953.
24. Haas T., Metzger J., Schmitz F., Heit A., Muller T., Latz E., et al. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 2008, 28(3):315-323.
25. Yasuda K., Rutz M., Schlatter B., Metzger J., Luppa P.B., Schmitz F., et al. CpG motif-independent activation of TLR9 upon endosomal translocation of natural phosphodiester DNA. Eur J Immunol 2006, 36(2):431-436.
26. Klinman D.M. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther 2004, 4(6):937-946.
27. Semple S.C., Klimuk S.K., Harasym T.O., Hope M.J. Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol 2000, 313:322-341.
28. Klinman D.M., Currie D., Gursel I., Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004, 199(1):201-216.
29. Chikh G.G., Kong S., Bally M.B., Meunier J-C., Schutze-Redelmeier M-P.M. Efficient delivery of antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T Cells. J Immunol 2001, 167(11):6462-6470.
30. Nakanishi T., Kunisawa J., Hayashi A., Tsutsumi Y., Kubo K., Nakagawa S., et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release 1999, 61(1-2):233-240.
31. Badiee A., Jaafari M.R., Samiei A., Soroush D., Khamesipour A. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol 2008, 15(4):668-674.
32. Jaafari M.R., Badiee A., Khamesipour A., Samiei A., Soroush D., Kheiri M.T., et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007, 25(32):6107-6117.
33. Javadian E., Nadim A., Tahvildare-Bidruni G., Assefi V. Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan part V: report on a focus of zoonotic cutaneous leishmaniasis in Esferayen. Bull Soc Pathol Exot Filiales 1976, 69(2):140-143.
34. Momeni A.Z., Jalayer T., Emamjomeh M., Khamesipour A., Zicker F., Ghassemi R.L., et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999, 17(5):466-472.
35. Sharifi I., FeKri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998, 351(9115):1540-1543.
36. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol 1987, 139(1):221-227.
37. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG Oligodeoxynucleotides act as adjuvants that Switch on T helper 1 (Th1) immunity. J Exp Med 1997, 186(10):1623-1631.
38. Weeratna R.D., Brazolot Millan C.L., McCluskie M.J., Davis H.L. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 2001, 32(1):65-71.
39. Badiee A., Jaafari M.R., Khamesipour A. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Exp Parasitol 2007, 115(2):127-134.
40. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981, 126(4):1614-1619.
41. Mutiso J.M., Macharia J.C., Gicheru M.M. A review of adjuvants for Leishmania vaccine candidates. J Biomed Res 2010, 24(1):16-25.
42. Afrin F., Rajesh R., Anam K., Gopinath M., Pal S., Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect Immun 2002, 70(12):6697-6706.
43. Sharma S.K., Dube A., Nadeem A., Khan S., Saleem I., Garg R., et al. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine 2006, 24(11):1800-1810.
44. Shimizu Y., Takagi H., Nakayama T., Yamakami K., Tadakuma T., Yokoyama N., et al. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunol 2007, 29(5):229-239.
45. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 1999, 96(12):6970-6975.
46. Rhee E.G., Mendez S., Shah J.A., Wu C-y Kirman J.R., Turon T.N., et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG Oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 2002, 195(12):1565-1573.
47. Tafaghodi M., Khamesipour A., Jaafari M.R. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN. Parasitol Res 2010, 108(5):1265-1273.
48. Iborra S., Parody N., Abanades D.R., Bonay P., Prates D., Novais F.O., et al. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect 2008, 10(10-11):1133-1141.
49. Ramirez L., Iborra S., Cortes J., Bonay P., Alonso C., Barral-Netto M., et al. BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge. J Biomed Biotechnol 2009, 2010:181690.
50. Agallou M., Margaroni M., Karagouni E. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Vaccine 2011, 29(31):5053-5064.
51. Dumont F.J. Modulation of Th1 and Th2 responses for immunotherapy. Exp Opin Ther Patents 2002, 12(3):341-367.
52. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813):740-745.
53. Lee K.W., Jung J., Lee Y., Kim T.Y., Choi S.Y., Park J., et al. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol 2006, 43(13):2107-2118.
54. Kwon H.J., Lee K.W., Yu S.H., Han J.H., Kim D.S. NF-kappaB-dependent regulation of tumor necrosis factor-alpha gene expression by CpG-oligodeoxynucleotides. Biochem Biophys Res Commun 2003, 311(1):129-138.
55. Datta N., Mukherjee S., Das L., Das P.K. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. Eur J Immunol 2003, 33(6):1508-1518.
56. Mui B., Raney S.G., Semple S.C., Hope M.J. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther 2001, 298(3):1185-1192.
57. Kim D., Rhee J.W., Kwon S., Kim Y.E., Choi S.Y., Park J., et al. Enhancement of immunomodulatory activity by liposome-encapsulated natural phosphodiester bond CpG-DNA in a human B cell line. BMB Rep 2010, 43(4):250-256.
58. De Oliveira M.C., Boutet V., Fattal E., Boquet D., Grognet J-M., Couvreur P., et al. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice. Life Sci 2000, 67(13):1625-1637.
59. Zhang Y.M., Rusckowski M., Liu N., Liu C., Hnatowich D.J. Cationic liposomes enhance cellular/nuclear localization of 99mTc-antisense oligonucleotides in target tumor cells. Cancer Biother Radiopharm 2001, 16(5):411-419.
60. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Ann Rev Immunol 2002, 20(1):709-760.
61. Mutwiri G.K., Nichani A.K., Babiuk S., Babiuk L.A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release 2004, 97(1):1-17.
62. Yan W., Chen W., Huang L. Mechanism of adjuvant activity of cationic liposome: Phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol 2007, 44(15):3672-3681.
63. Vangasseri D.P., Cui Z., Chen W., Hokey D.A., Falo L.D., Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membrane Biol 2006, 23(5):385-395.
64. Jiao X., Wang R.Y-H., Qiu Q., Alter H.J., Shih J.W-K. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol 2004, 85(6):1545-1553.
65. Li W.M., Dragowska W.H., Bally M.B., Schutze-Redelmeier M-P. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003, 21(23):3319-3329.
66. Suzuki Y., Wakita D., Chamoto K., Narita Y., Tsuji T., Takeshima T., et al. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 2004, 64(23):8754-8760.
67. Kamogawa Y., Minasi L.A., Carding S.R., Bottomly K., Flavell R.A. The relationship of IL-4- and IFN gamma-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 1993, 75(5):985-995.
68. Platzer C., Richter G., Uberla K., Muller W., Blocker H., Diamantstein T., et al. Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction. Eur J Immunol 1992, 22(5):1179-1184.
69. Noble A., Kemeny D.M. Interleukin-4 enhances interferon-gamma synthesis but inhibits development of interferon-gamma-producing cells. Immunology 1995, 85(3):357-363.
70. D'Andrea A., Ma X., Aste-Amezaga M., Paganin C., Trinchieri G. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J Exp Med 1995, 181(2):537-546.
71. Huang L.R., Chen F.L., Chen Y.T., Lin Y.M., Kung J.T. Potent induction of long-term CD8+ T cell memory by short-term IL-4 exposure during T cell receptor stimulation. Proc Natl Acad Sci USA 2000, 97(7):3406-3411.
72. Morrot A., Hafalla J.C., Cockburn I.A., Carvalho L.H., Zavala F. IL-4 receptor expression on CD8+ T cells is required for the development of protective memory responses against liver stages of malaria parasites. J Exp Med 2005, 202(4):551-560.
73. Stager S., Alexander J., Kirby A.C., Botto M., Rooijen N.V., Smith D.F., et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 2003, 9(10):1287-1292.
74. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002, 2(11):845-858.